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In the recent past, the discovery of the viral aetiology of
several human diseases, and major advances in our knowl-
edge of the steps of the viral life cycle, and the natural
history, pathogenesis and chemotherapy of viral diseases,
have led to the development of powerful assays for the
diagnosis of these diseases. Indeed, almost all central hospi-
tals and healthcare facilities in western countries have an
active viral diagnostic laboratory. The above process, how-
ever, took several decades, and is far from being complete,
with new methods and techniques currently being devel-
oped for the diagnosis, monitoring and characterization of
viral infections, and new and unexpected issues on the
topic being generated.
When the concept of ‘diagnosis of viral infection’ was
introduced, the major emphasis was placed on the isolation
of viruses and on ‘conventional’ serological tests. From the
very beginning, however, it was clear that virus isolation was
expensive and, above all, time-consuming, and that serologi-
cal tests required sera collected ‡10 days from the onset of
infection: in both cases, the tests frequently provided a diag-
nosis in retrospect.
Later, the clinical virology laboratory beneﬁted from
other, more modern, techniques, such as electron micros-
copy, immunoﬂuorescence, radioimmunoassay, and ELISAs.
As well as detecting antibodies to the viruses, some of these
methods were adapted to detect viruses directly in clinical
specimens. This yielded more rapid results, and a diagnosis
could sometimes be established on the day when the clinical
sample was collected, making the assays clinically useful.
More recently, dramatic advances in molecular techniques
have revolutionized the diagnosis of viral infections, together
with several other biomedical disciplines. The different
molecular techniques, known and utilized only in specialized
laboratories for decades, found application in clinical virology
laboratories. This represented a breakthrough whose impact,
to my mind, is still ongoing. Foremost has been the develop-
ment of PCR and, later, real-time PCR, which are highly sen-
sitive, speciﬁc, reproducible, relatively inexpensive and easy
to automate molecular technologies. Additionally, gene
sequencing technology has now matured into a modern tech-
nique that is able to yield results in a reasonable time at rea-
sonable cost. Thus, it is today possible to determine the
speciﬁc virus that the patient is harbouring, sequence it, and
measure its viral load in biological samples in a matter of few
days. This allows the clinician to monitor the infection or to
evaluate the efﬁcacy of an antiviral treatment in, to quote an
over-used term, real-time. In special circumstances, such as
human immunodeﬁciency virus, hepatitis B virus and hepati-
tis C virus infections, or viral infections in transplanted
patients, virological surveillance by sensitive and quantitative
molecular methods has become an essential part of the diag-
nostic routine, because the timely detection and monitoring
of virus copy numbers are prerequisites for successful pre-
emptive and therapeutic treatment approaches.
For the above reasons, concept and signiﬁcance of viral
diagnosis and inherent processes have changed in many
instances and along the years. The clinical virologist not only
has to identify the virus whose infection is associated with
deﬁnite symptoms, but must also provide insights to clini-
cians to help them deﬁne the course of infection, its progno-
sis, and eventually the efﬁcacy of therapy.
As stated before, the evolution of the viral diagnosis pro-
cess is far from complete. We are witnessing a burgeoning
development of impressive new diagnostic technologies, and
innovations are appearing in the ﬁeld.
This theme section aims to describe and discuss only
some of these new technologies, in the belief that, if prop-
erly and carefully utilized, they could soon become part of
the virology laboratory routine to assist the clinician in the
modern and cautious management of patients with viral
infections.
The technologies that are rapidly entering the ﬁeld include
the new techniques based on multiplex RT-PCR ampliﬁca-
tions followed by microarray analysis. This new assay has
already been applied in clinical virology laboratories for vari-
ous viral infections caused by deﬁnite viruses [1,2], and has
the potential of rapidly detecting and identifying viruses
directly in clinical specimens, including typing and subtyping
of a broad panel of common and newly discovered human
viral pathogens. Some of the reagents have found rapid appli-
cations and have become commercially available, but the
wide-scale application of the technology in clinical virology
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laboratories merits awareness and attention. The latter argu-
ments are the main topic of the review by Andreoletti’s
group [3] in this issue.
Major advances in nucleic acid sequencing technologies,
often referred to as ‘next-generation sequencing’, have pro-
duced an outright revolution, providing a new opportunity for
the diagnosis of viral infections. This process has already been
applied at the diagnostic level for some viral infections, leading
to the discovery of new viruses, sequencing of the whole viral
genomes present in clinical specimens and/or the detection of
minor viral variants that may have clinical relevance, which
were previously not possible with conventional methods [4,5].
In this issue, Capobianchi et al. [6] discuss what is currently
known about the possibility of wider application of next-gen-
eration sequencing in clinical virology laboratories.
‘Omics’ technologies, such as genomics and transcripto-
mics, have greatly enhanced the systematic evaluation of gene
expression. Despite their usefulness, the limitations of genom-
ics and transcriptomics approaches are well known, and this is
also true in clinical virology. For instance, virus–host interac-
tions cannot be easily predicted by genomics and transcripto-
mics, as gene mutations and mRNA expression levels often do
not necessarily mirror the actual situation in terms of mature
and functional proteins, owing to the possibility of post-trans-
lational regulation. In light of the above considerations, the
major advances in mass spectrometry-based proteomics tech-
nologies may provide a unique tool for structural and func-
tional analysis of the effectors of biological functions, and this
may ﬁnd useful applications in virology, shedding more light on
host–virus interactions. At present, this approach has been
applied to viral infections in some cases [7–9], but, in my opin-
ion, it has the possibility of wide application, especially in clini-
cal situations where knowledge of the pathogenetic
mechanism of the viral infection may help in disease manage-
ment. These aspects are addressed in this issue by Tripodi’s
group [10], who mainly discuss the potential of mass spec-
trometry proteomics in viral infections, focusing essentially on
hepatitis C virus infection.
Irrespective of the type of new technique addressed, the
quality of diagnostic results is of paramount importance.
Indeed, for the future, there is a pivotal need to concentrate
on the issue of ensuring quality results in terms of accuracy.
As logistic factors sometimes prevent the institutional enti-
ties operating in parallel with the rapid acquisition of new
technical knowledge, other approaches can be used. The
above topics are discussed in the review by Ieven et al. [11]
in this issue.
The theme section does not tackle another, to my mind,
very important issue. The clinical virology laboratory is, and
in the immediate future will be increasingly, able to provide
an enormous amount of detailed data on the characterization
of the patient harbouring viruses and, eventually, the effec-
tors of the mechanism of pathogenesis and recovery from
the infection. The leading task is to translate all of these new
ﬁndings into the patient’s clinical management, in an attempt
to monitor the infections and readily predict the efﬁcacy of
an antiviral treatment or give a reasonable prognosis. This
necessarily entails a reappraisal of and an emphasis on the
role of the clinical virologist, who has to work alongside cli-
nicians to manage patients and their treatment. This means
that communication between laboratory personnel and clini-
cians (which, for logistic reasons, large hospitals might lack)
is vital to ensure that the diagnostic process is carried out
properly.
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